(Bloomberg) -- A biotechnology startup working to bring back animals from extinction has raised $200 million at a valuation of $10.2 billion, more than six times its valuation just two years ago.

But Ben Lamm, CEO and founder of Colossal Biosciences, has said he's 'positive' the first woolly mammoth calves will be born in the next few years. 'Our recent successes in creating the ...

Colossal Biosciences Inc. is using DNA and genomics to try to resurrect the dodo, Tasmanian tiger and the woolly mammoth. Co-founder and Chief Executive Officer Ben Lamm says the company is on track ...

Colossal has made headlines in the past for its plans to bring back the woolly mammoth, the thylacine — commonly referred as the Tasmanian tiger — and the dodo bird. The Texas-based company ...

Colossal Biosciences, the US company aiming to bring back extinct species, says that it expects its first woolly mammoth calves will be born during the next three years. "Within the next two years ...

Digital rendering of the long-extinct woolly mammoth. Courtesy Colossal Biosciences ... startup founded in Texas to be valued at eleven figures, the new funding round will bolster Colossal ...

Colossal Biosciences, the company that’s famously on a mission to bring back the woolly mammoth and two other extinct species, has raised a $200 million Series C at a $10.2 billion valuation ...